ARTICLE | Emerging Company Profile
Tessellate: Identifying new synthetic lethality pairs
Netherlands-based newco aims to extend the concept beyond patients with homologous recombination deficiency
August 4, 2025 11:29 PM UTC
Tessellate is identifying new synthetic lethality relationships to extend the clinically validated idea to new patient populations.
Tessellate Bio B.V. CEO Blaukat was SVP and head of oncology research at Merck KGaA (Xetra:MRK), when two former Merck Venture colleagues, who had moved to Biogeneration Ventures and Forbion, approached him to lead the biotech. ...